CRSP - CRISPR Therapeutics AG

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
48.92
+0.25 (+0.51%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close48.67
Open49.12
Bid46.00 x 800
Ask49.73 x 900
Day's Range48.06 - 49.77
52 Week Range16.16 - 73.90
Volume401,709
Avg. Volume1,341,235
Market Cap2.328B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.11
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est67.07
Trade prices are not sourced from all markets
  • Cramer's lightning round: If Zuora's stock dips, buy more
    CNBC Videos13 days ago

    Cramer's lightning round: If Zuora's stock dips, buy more

    Jim Cramer zooms through his take on callers' favorite stocks, including a play on the growing subscription economy.

  • The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed
    Motley Fool36 minutes ago

    The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed

    Get ready for a golden age of medicine that could dramatically shake up which biotechs get the gold.

  • How Analysts Rate Editas Medicine and Peers in August
    Market Realist11 days ago

    How Analysts Rate Editas Medicine and Peers in August

    Editas Medicine (EDIT) is a research-stage genome editing company. Editas makes use of clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology and has developed a proprietary genome editing platform based on it with a product development strategy to chiefly target genetically defined diseases.

  • Is Crispr Therapeutics Stock Grossly Overvalued?
    Motley Fool12 days ago

    Is Crispr Therapeutics Stock Grossly Overvalued?

    Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?

  • Benzinga12 days ago

    Jim Cramer Advises His Viewers On Visa, Zuora And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said he would take profits in Crispr Therapeutics AG (NASDAQ: CRSP ). Enable Midstream Partners LP (NYSE: ENBL ) pays a good dividend, said ...

  • GlobeNewswire14 days ago

    CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results

    -Obtained Approvals of CTAs in Multiple Countries for CTX001 in β-thalassemia and SCD-- Initiation of Clinical Trials for CTX001 in β-thalassemia and SCD on Track for 2018-- Preclinical Studies for CTX110 ...

  • Here's Why CRISPR Therapeutics Lost 18.8% in July
    Motley Fool17 days ago

    Here's Why CRISPR Therapeutics Lost 18.8% in July

    The gene-editing pioneer (and its peers) faced more pressure from a study highlighting the unknowns of CRISPR tools.

  • Barrons.com18 days ago

    [$$] CRISPR Technology Still Holds Big Promise

    The gene-editing technology called CRISPR has worked such wonders in laboratories that Wall Street values the technique’s three pioneers at a collective $5 billion, even though nobody’s tested the stuff in people yet. A shudder recently ran through the stocks—Crispr Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA)—after a few scientific studies raised concerns that gene-editing therapy might have serious side effects. If you don’t need to put CRISPR in humans, then side effects are not an issue.

  • Why These Gene-Editing Companies Took a Tumble in July
    Market Realist21 days ago

    Why These Gene-Editing Companies Took a Tumble in July

    The stock prices of gene-editing companies like CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA) saw a sharp correction in July. These companies are focused on clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology, and have fallen on concerns stemming from a recently published study.

  • Here's Why Vertex Pharmaceuticals Earnings Are Growing Faster Than Revenue
    Motley Fool22 days ago

    Here's Why Vertex Pharmaceuticals Earnings Are Growing Faster Than Revenue

    The biotech benefits from economies of scale.

  • Intellia Therapeutics, Inc. Stock History: The Story of a CRISPR Gene Editing Pioneer
    Motley Fool24 days ago

    Intellia Therapeutics, Inc. Stock History: The Story of a CRISPR Gene Editing Pioneer

    How Intellia Therapeutics quickly became one of the top gene-editing biotech stocks on the market.

  • 3 Reasons Why Vertex Pharmaceuticals Stock Isn't Nearly as Expensive as It Looks
    Motley Fool25 days ago

    3 Reasons Why Vertex Pharmaceuticals Stock Isn't Nearly as Expensive as It Looks

    The market isn't fully appreciating just how much more room this biotech has to grow.

  • Vertex Pharmaceuticals (VRTX) Q2 2018 Earnings Conference Call Transcript
    Motley Fool26 days ago

    Vertex Pharmaceuticals (VRTX) Q2 2018 Earnings Conference Call Transcript

    VRTX earnings call for the period ending June 30, 2018.

  • ACCESSWIRE27 days ago

    Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Editas Medicine

    NEW YORK, NY / ACCESSWIRE / July 25, 2018 / U.S. markets finished moderately higher on Tuesday, fueled by strong corporate earnings as Google quarterly results topped expectations. The Dow Jones Industrial ...

  • Here's Why CRISPR Stocks Are Down as Much as 11.4% Today
    Motley Fool28 days ago

    Here's Why CRISPR Stocks Are Down as Much as 11.4% Today

    These companies are reeling from last week's study showing potentially negative effects from their gene-engineering tools.

  • ACCESSWIRE28 days ago

    Free Research Reports on CorMedix and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on CRMD sign up now at www.wallstequities.com/registration. Markets served include medical, agricultural, environmental, and industrial.Lined up for scanning this morning are the following equities: Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), CorMedix Inc. (NYSE AMER: CRMD), CRISPR Therapeutics AG (NASDAQ: CRSP), and Endocyte Inc. (NASDAQ: ECYT).

  • Yet Another CRISPR Worry: What Should Investors Do?
    Motley Foollast month

    Yet Another CRISPR Worry: What Should Investors Do?

    A new paper suggests that CRISPR-Cas9 could cause unintended changes to DNA.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Tonix Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 17, 2018 / U.S. markets closed mostly lower on Monday, as upbeat economic data and the latest batch of corporate earnings failed to encourage investors. The Dow Jones Industrial ...

  • The Wall Street Journallast month

    [$$] New Research Prompts Selloff in Companies Using Crispr Technology

    Shares of companies developing therapies using the gene-editing technology Crispr declined Monday following the publication of research suggesting Crispr could cause far more extensive DNA damage than previously thought, leading to potentially harmful health effects for patients. The study, published in the journal Nature Biotechnology, said the changes were often at places far away from the intentional edit, and so went undetected in previous studies, which typically observed smaller sections of genetic material. The latest paper adds to a growing body of research highlighting obstacles in developing the gene-editing technology, which has generated public interest and huge investment as a method that could potentially treat intractable genetic diseases.

  • InvestorPlacelast month

    A Single Study Is No Reason to Sell Crispr Stock

    Crispr Therapeutics (NASDAQ:CRSP) is down on Monday after an article in today’s issue of Nature (one of the most-trusted, well-known scientific journals) raised concerns about Crispr’s gene-editing technology. As of this writing, Crispr stock is down 7.9%. Crispr is a revolutionary gene-editing technology that has been widely embraced by the scientific community.

  • Reuterslast month

    CRISPR gene editing can cause risky collateral DNA damage - study

    Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells. The findings, published in the journal Nature Biotechnology on Monday, have safety implications for gene therapies that are being developed using CRISPR/Cas9 - a type of molecular scissor technology that can be used to edit DNA. "We found that changes in the DNA have been seriously underestimated before now," said Allan Bradley, a professor at Britain's Wellcome Sanger Institute who co-led the research published on Monday.

  • CRISPR Therapeutics Stock History: The Rise of the World's Biggest Gene-Editing Biotech
    Motley Foollast month

    CRISPR Therapeutics Stock History: The Rise of the World's Biggest Gene-Editing Biotech

    This biotech has risen to the top of the CRISPR-Cas9 gene editing world. Here's how CRISPR Therapeutics did it.

  • MarketWatchlast month

    Gene-editing stocks tumble on concerns about DNA damage

    MARKET PULSE Shares of companies developing CRISPR gene-editing therapies dropped in Monday morning trade after a study found that the technique can damage DNA. The research, published in the peer-reviewed journal Nature Biotechology, is just the latest questioning whether the technique brings more benefit than harms to patients, with a report in June raising the possibility that edited cells could cause cancer.

  • Here's Why CRISPR Stocks Have Gained as Much as 169% in 2018 (So Far)
    Motley Foollast month

    Here's Why CRISPR Stocks Have Gained as Much as 169% in 2018 (So Far)

    Investors are bidding up shares as the first drug candidates using the gene-editing technology inch closer to the clinic.

  • Here's Why CRISPR Therapeutics AG Fell 14.7% in June
    Motley Foollast month

    Here's Why CRISPR Therapeutics AG Fell 14.7% in June

    Investors began paying closer attention to the results from two studies suggesting a link between certain gene-editing tools and cancer.